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Glucagon-like peptide-1 receptor expressing
cells in the mouse brainSimon C. Cork 1, James E. Richards 1, Marie K. Holt 1, Fiona M. Gribble 2, Frank Reimann 2, Stefan Trapp 1,*ABSTRACT
Objective: Although Glucagon-like peptide 1 is a key regulator of energy metabolism and food intake, the precise location of GLP-1 receptors and
the physiological relevance of certain populations is debatable. This study investigated the novel GLP-1R-Cre mouse as a functional tool to
address this question.
Methods: Mice expressing Cre-recombinase under the Glp1r promoter were crossed with either a ROSA26 eYFP or tdRFP reporter strain to
identify GLP-1R expressing cells. Patch-clamp recordings were performed on tdRFP-positive neurons in acute coronal brain slices from adult mice
and selective targeting of GLP-1R cells in vivo was achieved using viral gene delivery.
Results: Large numbers of eYFP or tdRFP immunoreactive cells were found in the circumventricular organs, amygdala, hypothalamic nuclei and
the ventrolateral medulla. Smaller numbers were observed in the nucleus of the solitary tract and the thalamic paraventricular nucleus. However,
tdRFP positive neurons were also found in areas without preproglucagon-neuronal projections like hippocampus and cortex. GLP-1R cells were
not immunoreactive for GFAP or parvalbumin although some were catecholaminergic. GLP-1R expression was conﬁrmed in whole-cell recordings
from BNST, hippocampus and PVN, where 100 nM GLP-1 elicited a reversible inward current or depolarisation. Additionally, a unilateral ste-
reotaxic injection of a cre-dependent AAV into the PVN demonstrated that tdRFP-positive cells express cre-recombinase facilitating virally-
mediated eYFP expression.
Conclusions: This study is a comprehensive description and phenotypic analysis of GLP-1R expression in the mouse CNS. We demonstrate the
power of combining the GLP-1R-CRE mouse with a virus to generate a selective molecular handle enabling future in vivo investigation as to their
physiological importance.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Glucagon-like peptide 1 (GLP-1) is traditionally recognised as a pe-
ripheral incretin hormone. Released postprandially from intestinal L-
cells, it binds to GLP-1 receptors (GLP-1R) on pancreatic b-cells to
increase insulin secretion. Additionally, GLP-1 acts as a neuropeptide
and is produced by preproglucagon (PPG) neurons located in the lower
brainstem, primarily in the caudal nucleus tractus solitarii (NTS) and
the intermediate reticular nucleus [1,2].
Numerous rodent studies have addressed the question of GLP-1’s
action within the brain (for review see: [3,4]). Most studies have
examined the effects of cerebroventricular injection of GLP-1 or its
stable analogue exendin-4 (Ex-4) on food intake [5], but other reported1Centre for Cardiovascular and Metabolic Neuroscience, Department of Neuroscienc
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effects on learning, memory and thermogenesis [6e9]. Furthermore,
central GLP-1 appears to be involved in mediating the rewarding effect
of food. Activation of GLP-1R within the ventral tegmental area (VTA)
and nucleus accumbens (NAc) results in a signiﬁcant decrease in the
consumption of high calorie food and reduced body weight gain over
24 h [10].
Although the exact mechanism by which GLP-1 affects the brain is
unclear, it has been demonstrated that within the VTA and NAc, GLP-1
appears to bind to presynaptic GLP-1R on glutamatergic terminals
facilitating glutamate release, without triggering direct postsynaptic
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It has previously been shown that GLP-1 producing neurons in the NTS
send ascending axons to forebrain and brainstem regions associated
with metabolic and autonomic control in the mouse, including the
arcuate nucleus (ARC), hypothalamic paraventricular nucleus (PVN),
rostral ventrolateral medulla and dorsomedial hypothalamus (DMH)
[1,13]. These projections correlate well with the pattern of GLP-1R
expression throughout the brain of the rat [14].
Given the potent effects of central GLP-1 on food intake, it is important
to fully elucidate the exact expression proﬁle of GLP-1R throughout the
brain. The distribution of GLP-1R mRNA has previously been assessed
in the rat brain by in situ hybridisation [14]; however, little is known
about the distribution in mouse. This gap in knowledge is notable,
especially given the increased usage of transgenic mouse models in
metabolic physiology.
Here we detail the distribution of GLP-1R expressing cells throughout
the mouse brain using a novel transgenic model, in which cre-
recombinase is expressed under the control of the Glp1r gene. We
show that GLP-1R expression correlates well with that observed in the
rat [14], non-human primates [15] and with the projection pattern of
mouse PPG neurons [1,13]. We also demonstrate that GLP-1R
expressing cells do not exhibit immunoreactivity for glial ﬁbrillary
acid protein (GFAP) or parvalbumin (PARV), but do show tyrosine hy-
droxylase (TH) immunoreactivity in some areas. Furthermore, we
establish that this mouse model is amenable to manipulation of spe-
ciﬁc subsets of GLP-1R expressing cells with cre-dependent viral gene
transfer. Finally, we assess the feasibility of using this mouse model for
in vitro analysis using brain slice patch-clamp recordings by recording
electrical responses to exogenous GLP-1 from GLP-1R expressing cells
in several brain regions.
2. MATERIAL AND METHODS
2.1. Animals
All animal experimentation was carried out in accordance with the UK
Animals (Scientiﬁc Procedures) Act, 1986, and had the required ethical
approval. The entire study was performed on GLP-1R-CRE mice that
express cre-recombinase under the Glp1r promoter. Generation of
these mice has been described in detail before [16]. These mice were
crossed with ROSA26-tdRFP or ROSA26-eYFP reporter strains [17] to
enable ﬂuorescent detection of cells expressing GLP-1R by cytosolic
tdRFP or eYFP expression, respectively. A total of 3 GLP-1R-CRE-eYFP
and 8 GLP-1R-CRE-tdRFP mice of both sexes were used for the
immunoﬂuorescence study, whereas the electrophysiological study
was performed entirely with the GLP-1R-CRE-tdRFP strain. Mice were
kept on a 12 h light e 12 h dark cycle, had access to food and water
ad libitum, and were 8e16 weeks old (weighing between 25 and 35 g)
when used for experiments. Females were consistently lighter than
males.
2.2. Immunoﬂuorescence
Mice were anaesthetised with urethane (1.5 g/kg; i.p.) and perfuse-
ﬁxed transcardially with heparinised 0.1M phosphate buffer (PB) fol-
lowed by 4% paraformaldehyde in 0.1M PB, pH 7.4. Brains were
removed from skulls, post-ﬁxed overnight in the same ﬁxative before
being cryoprotected in 30% sucrose in 0.1M PB. Brains were sectioned
coronally at a thickness of 30 mm (1:5 series) from the olfactory bulbs
to the spinomedullary junction.
2.2.1. Immunohistochemical identiﬁcation of eYFP or tdRFP
Tissues were blocked with 0.1% Triton X-100 and 10% normal goat
serum diluted in 0.1M PB for 1 h at room temperature. GLP-1R-MOLECULAR METABOLISM 4 (2015) 718e731  2015 The Authors. Published by Elsevier GmbH. This is an o
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green ﬂuorescent protein (GFP; Catalogue #AB13970, lot #623923;
Abcam, Cambridge MA, USA) or dsRED (Clontech #632496). These
were added to the blocking solution in a 1:1000 dilution and incubated
overnight at 4 C. Subsequently, sections were washed 3 times for
5 min in 0.1M PB at room temperature, followed by incubation with a
ﬂuorescently labelled secondary antibody (1:500 dilution) in blocking
solution for 2 h. Either an anti-chicken Alexa Fluor 488 (Catalogue# A-
11039, Invitrogen) or an anti-rabbit Cy3 (Catalogue# C2306, Sigma
Aldrich, St Louis MO, USA) was used. Sections were washed again as
previously described, then mounted onto polylysine-coated slides
(Catalogue# 631-1349, VWR), air dried and coverslipped with Vecta-
shield mounting medium (Catalogue# H-1200, Vector Labs).
2.2.2. Double immunoﬂuorescence
Staining was performed as described above with the exception of
using sheep serum rather than goat for TH staining. Sections were then
incubated with anti-GFP and anti-TH (1:1000 dilution, catalogue# sc-
14007, Santa Cruz) or anti-GFP and anti-GFAP conjugated to Cy3
(catalogue# C9205, Sigma Aldrich, St Louis MO, USA), or anti-dsRED
and anti-parvalbumin (1:5000 dilution, catalogue# 235, Swant,
Switzerland) overnight at 4 C. Following primary antibody incubation
sections were washed as previously described and incubated with the
appropriate secondary antibody: for TH the anti-rabbit conjugated to
Cy3, and for parvalbumin the Alexa Fluor 488 goat anti-mouse
(catalogue# A10680, Invitrogen), respectively. Sections were then
washed and mounted as described above.
2.2.3. Data collection and analysis
Stained sections were analysed on an upright epi-ﬂuorescence mi-
croscope (Leica DMRB, Leica Microsystems, Milton Keynes, UK)
equipped with a Retiga 3000 colour digital camera (QImaging, Surrey,
Canada). Images were captured using QCapture software (QImaging)
and subsequently exported to Corel Photo-Paint X3 (Corel Corporation,
Ottawa, Canada) where brightness and contrast were adjusted.
Microsoft Image Composite Editor (Microsoft Corporation, Redmond,
USA) was used to produce montages from several frames.
2.3. Viral targeting
Adeno-associated virus (AAV) particles were produced as described by
Murray et al. [18]. Brieﬂy, to produce rAAV virions containing a 1:1 ratio
of type 1 and type 2 capsid proteins human embryonic kidney (HEK)
293 cells were co-transfected with the AAV plasmid pAAV-EF1a-
double ﬂoxed-hChR2(H134R)-EYFP-WPRE-HGHpA (Addgene plasmid
# 20298) and AAV1 (pH21), AAV2 (pRV1) helper plasmids as well as
the adenovirus helper plasmid pFD6 using calcium phosphate.
64 h post-transfection, cells were harvested, digested with sodium
deoxycholate allowing AAVs to be puriﬁed from lysates using 1 ml
HiTrap heparin columns (Sigma). Eluted virions were concentrated
using Amicon Ultra-4 centrifugal ﬁlter devices (Millipore U FC810024).
Adult GLP-1R-CREetdRFP mice were anaesthetised with ketamine
(75 mg/kg; i.m.) and medetomidine (0.5 mg/kg; i.m.). Deep anaes-
thesia was conﬁrmed by the absence of a pedal withdrawal reﬂex to a
toe pinch. The head was ﬁxed in a stereotaxic frame and the skull was
exposed to allow a cranial window to be drilled at the correct location
for a unilateral microinjection (150 nl; 50 nl/min) of a solution con-
taining viral particles of EF1a-double ﬂoxed-hChR2(H134R)-EYFP AAV
serotype 1/2 to target GLP-1R neurons. The coordinates used to target
the PVN were 0.82 mm caudal and 0.1 mm lateral from Bregma and
4.75 mm ventral from the surface of the skull at Bregma. After removal
of the injection needle the skin was sutured and anaesthesia reversedpen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 719
Figure 1: GLP-1 receptor expressing cells in the CNS. A, B. Demonstrates the reporter expression in the dorsal vagal complex of the eYFP and tdRFP mice. Expression was
equivalent in the area postrema (AP), nucleus tractus solitarius (NTS) and dorsal motor nucleus of the vagus (DMV). High levels of reporter expression were observed in the area
postrema (A, B) dorsal lateral septum, subfornical organ (C), ventrolateral hypothalamus, arcuate (D), hypothalamic paraventricular nucleus (E) superior colliculus and peri-
aqueductal grey (F). Expression was also observed, albeit at lower levels, in the nucleus tractus solitarius (A, B), dorsomedial hypothalamus (D), hippocampus, geniculate, thalamic
reticular formation and mammilliary nucleus (F). Scale bars: A, B, E ¼ 200 mm. C, F ¼ 1 mm. D ¼ 500 mm. Abbr: CC: central canal, AP: area postrema, NTS: nucleus tractus
solitarius, LSD: dorsal lateral septum, SFO: subfornical organ, DMH: dorsomedial hypothalamus, VMH: ventromedial hypothalamus, ARC: arcuate nucleus, DG: dentate gyrus, Gen:
geniculate nucleus, SC: superior colliculus, PAG: periaqueductal grey, CoA: cortical amygdala, TRt: thalamic reticular formation, Mamm: mammillary nucleus, PVN: paraventricular
nucleus, 3V: 3rd ventricle.
Original articlewith atipamezole (1 mg/kg; i.m.). Post-operative analgesia (Bupre-
norphine, 0.05 mg/kg per day, s.c) was given for two days. Viruses
were incubated for 3 weeks before injected animals were trans-
cardially perfused-ﬁxed as detailed above.
2.4. Electrophysiology
Coronal (250 mm thick) brain slices were obtained from adult
transgenic mice of either sex as described previously [2]. Slices were
kept at 34 C in artiﬁcial cerebrospinal ﬂuid (ACSF) of the following
composition (in mmol/l): 118 NaCl, 3 KCl, 25 NaHCO3, 1 MgCl2, 2
CaCl2, 10 glucose; pH 7.4. Experimental solutions were constantly
bubbled with 95% O2/5% CO2. Glucagon-like peptide 1 (7e36)
amide (#2082) was obtained from R&D systems and prepared as a
100 mM stock solution in MilliQ H2O. Whole-cell recording were
carried out in ACSF at 28e32 C using a ‘low Cl’ pipette solution of720 MOLECULAR METABOLISM 4 (2015) 718e731  2015 The Authors. Published by Ethe following composition (in mM): 120 K-gluconate, 5 HEPES, 5
BAPTA, 1 NaOH, 1 MgCl2, 1 CaCl2, and 5 K2ATP, 0.25 NaGTP; pH 7.2.
The junction potential of 10 mV for this pipette solution was added
ofﬂine. All ﬁgures and values in the results are corrected for the
junction potential.
Patch-clamp recordings in the voltage-clamp or current-clamp mode
were performed on visually identiﬁed red ﬂuorescent cells within the
bed nucleus of the stria terminalis (BNST), the hypothalamic PVN and
the hippocampus using an EPC-9 ampliﬁer and Pulse/Pulseﬁt software
(HEKA-Electronics, Germany). In voltage-clamp membrane resistance
was determined by 500 ms hyperpolarising voltage pulses of 40 mV
amplitude from the holding potential every 20s. Data are given as
mean  one S.E.M. Statistical signiﬁcance was tested using a paired
or unpaired t-test as appropriate, p-values < 0.05 (*) or < 0.01 (**)
were considered signiﬁcant.lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1 e Location of GLP-1R expressing cells in this study, compared to
PPG neuron projections [1] in mouse, detected by transgene expression, rat
GLP-1R expression, analysed by in situ hybridisation [14], and non-human











Granule cell layer þþ N/A N/A N/A
Anterior olfactory area
Dorsal þþ N/A N/A N/A
Lateral þþþ N/A N/A N/A
Ventral þþþ N/A N/A N/A
Nucleus accumbens N/A þa þþa
Shell þ
Core þ
Ventral tenia tecta þþ N/A N/A N/A
Claustrum þþ N/A N/A N/A
Lateral Septum þa
Intermediate þþ N/A þþ
Dorsal þþþþ N/A N/A
Ventral þþþ N/A N/A
Subfornical organ þþþþ N/A N/A N/A
Cortex þ -a -a
Cingulate þ N/A
Piriform þþ So
Bed nucleus of the stria terminalis þþþ þþþ þ þþ
Septohypothalamic nuclei þþ N/A N/A N/A
Preoptic area
Medial þ N/A N/A N/A
Lateral þ N/A N/A N/A
Ventral þþ þþ N/A N/A
Median þþ N/A N/A N/A
Hippocampus þa
CA3
Rostral þ e e
Caudal þþþ N/A þ
CA1 (Caudal) þþ N/A N/A
Dentate gyrus þþ e N/A N/A
Central Amygdala þþþþ þ e þþþ
Medial Amygdala þþþ N/A e þþ
Basolateral Amygdala þþ N/A N/A N/A
Cortical Amygdala þþ N/A N/A N/A
Organum vasculosum laminae
terminalis
þ þþ N/A N/A
Diencephalon
Thalamus
Anterior thalamic nuclei þþþ N/A e N/A
Ventral posteriomedial thalamic
nuclei
þþþ N/A N/A N/A
Paraventricular nucleus þ þþþ N/A þþ




Zona incerta þþþ N/A þþ e
Nucleus reuniens þþ N/A þ N/A
Parasubthalamic nucleus þ N/A N/A N/A
Ventral anterior thalamic nucleus þþþ N/A N/A N/A
Posterior thalamus þþþ N/A N/A e
Parafascicular thalamic nucleus þþ N/A þþþ N/A
Precommissural nucleus þþþ N/A N/A N/A
Mediodorsal nucleus þþþþ N/A N/A N/A
Ventromedial thalamic nucleus þþ N/A N/A N/A
Lateral habenular nucleus þþ N/A N/A N/A
Thalamic reticular formation þþ N/A N/A N/A
Hypothalamus
Anterior hypothalamus þþ þþ N/A N/A
Dorsomedial hypothalamus þþ þþþþ þ þþ
Paraventricular nucleus þþþ þþþþ þþþþ þþþ
Arcuate nucleus þþþ þþþ þþþþ þþþþ
(continued on next page)
Table 1 e (continued )
Lateral Hypothalamus þþ þþþ þ þþ
Posterior hypothalamus þþ N/A N/A N/A
Suprachiasmatic nucleus þþþ N/A N/A N/A
Retrochiasmatic nucleus þþþ N/A N/A N/A
Accessory neurosecretory nuclei þþ N/A N/A N/A
Ventromedial hypothalamus þþþ þþ þ e
Mesencephalon
Periaqueductal grey þþþ þþþ þþþ þ
Premamilliary nucleus þ N/A N/A N/A
Mammilliary nucleus þþ N/A N/A N/A
Posterior commissure þþþ N/A N/A N/A





Superior colliculus þþþ N/A þþb N/A
Ventral tegmental area þ N/A þþ þþ
Parasubthalamic nucleus þþ N/A N/A N/A
Brainstem
Area postrema þþþþ þ þþþþ þþþþ
Nucleus tractus solitarius þ þþ þþþ þþ
Nucleus of Roller þ N/A N/A N/A
Reticular formation þþ þþ N/A þ
Rostral ventrolateral medulla þþ þþþ N/A N/A
Locus Coeruleus þþ þþþ N/A þ
N/A e no information available; So: somata.
a Analysis of GLP-1R expression for these areas in rat/monkey is not subdivided by
region.
b Analysis of GLP-1R expression for these areas in rat/monkey has been further
subdivided, but not in mouse.
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GLP-1R-tdRFP and -eYFP expressing mice showed similar intensity of
ﬂuorescent reporter expression throughout the murine brain, with both
strains exhibiting good somatic and proximal neurite staining. Distal
neurites were only observed in certain brain regions, assumed to be a
result of lower cell density. For example, cells in the PVN showed
somatic and proximal neurite staining only, whereas cells in the BNST
showed both proximal and more distal neurite staining. Both tdRFP-
and eYFP-expressing mice were used in this study and both tdRFP-
and eYFP-immunoreactive cells will hereby be referred to as GLP-1R
cells.
3.1. Distribution of GLP-1R cells
GLP-1R expressing neurons were examined from the spinomedullary
junction to the olfactory bulb of the mouse brain. Densely grouped GLP-
1R neurons were observed both in the area postrema (AP; Figure 1A, B)
and in the subfornical organ (SFO; Figure 1C), indicating sites where
gut-released GLP-1 may directly inﬂuence neuronal activity. Interest-
ingly, only few GLP-1R cells were found in the organum vasculosum
lamina terminalis, the most rostral circumventricular organ. Many GLP-
1R neurons were also found throughout hypothalamic nuclei
(Figure 1DeE), particularly in the PVN, DMH and ARC, in-line with in
situ hybridisation and immunocytochemical studies from rat and pri-
mate (Table 1). Furthermore, considerable numbers of GLP-1R neu-
rons were observed in the periaqueductal grey, the mammillary recess,
the central nucleus of the amygdala and the caudal hippocampus
(Figure 1F).
A schematic representation of the distribution of GLP-1R neurons
throughout the mouse brain is given in Figure 2 and the density of GLP-
1R neurons in individual brain nuclei is quantiﬁed in Table 1. Within thepen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 721
Figure 2: Diagrams of coronal sections showing the distribution of GLP-1R expressing cell bodies in the brains of GLP-1R-Cre mice. Filled circles represent the presence of YFP- or
RFP-immunoreactive somata. The density of the ﬁlled circles indicates the relative density of the RFP-positive somata in each brain region. Drawings are based on the Paxinos
Mouse Brain Atlas and numerical values next to each section indicate the rostro-caudal position in relation to Bregma. Abbreviations: PrL, prelimbic cortex; FrA, frontal association
cortex; MO, medial orbital cortex; EPI, external plexiform layer; LS, lateral septum; AcbC, nucleus accumbens core; AcbS, nucleus accumbens shell; MS, medial septum nucleus; Cl,
claustrum; Pir, piriform cortex; Cpu, caudate putamen; BNST-D/V, bed nucleus of the stria terminalis dorsal/ventral; PO, preoptic area; MPO, medial preoptic area; MnPO, median
preoptic area; SFO, subfornical organ; Re, reuniens thalamic nucleus; PVN, paraventricular nucleus; LH, lateral hypothalamus; ARC, arcuate nucleus; Rt, reticular nucleus; PVT,
thalamic paraventricular nucleus; VPM, ventral posteromedial thalamic nucleus; CeA, central amygdala; BLA, basolateral amygdala; DMH, dorsomedial hypothalamus; VMH,
ventromedial hypothalamus; PAG, periaqueductal grey area; PH, posterior hypothalamus; PSTh, parasubthalamic nucleus; MM, mammillary nucleus; DG, dentate gyrus; DLG,
dorsolateral geniculate nucleus; PGMC, pregeniculate nucleus magnocellular part; SCol, superior colliculus; VTA, ventral tegmental area; MG, medial geniculate nucleus; AP, area
postrema; NTS, nucleus tractus solitarius; XII, hypoglossal nucleus; Ro, nucleus of roller; IRt, intermediate reticular nucleus; MdD, dorsal medullary reticular nucleus; RVLM, rostral
ventrolateral medulla.
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lower brainstem, GLP-1R neurons were scattered towards the lateral
aspects of the NTS and throughout the intermediate reticular nucleus.
Scattered neurons were also observed in the rostral ventrolateral
medulla, locus coeruleus and nucleus of Roller. Further rostral few
neurons were observed in the geniculate nucleus, mammillary nu-
cleus, pretectal nucleus, and superior colliculus.
In the diencephalon, GLP-1R neurons were located at a high density
throughout the hypothalamus, particularly in the magnocellular and
parvocellular subdivisions of the PVN, DMH and ARC, whereas
smaller numbers of neurons were scattered throughout the lateral
and posterior hypothalamus. In the thalamus, GLP-1R neurons were
observed in the ventral thalamic nuclei, the paraventricular nucleus,
the zona incerta, the nucleus reuniens, parasubthalamic nucleus,
reticular thalamic nucleus, posterior thalamus, parafascicular thal-
amus and precommissural area. In the hippocampus, few neurons
were observed in the rostral aspect of the CA3 region and the dentate
gyrus. Many more neurons, however, were observed in the caudal
CA3 and CA1 regions where the hippocampus extends ventrally
(Figure 1F). In the telencephalon, expression was observed in the
plexiform cell layer of the olfactory bulb, posterior and ventral sub-
nuclei of the BNST (Figures 1C and 3C), lateral septum (Figure 3E,
ventral tenia tecta, claustrum (Figure 3B), preoptic area, SFO, central,
medial and basolateral amygdaloid nuclei (Figure 3D). Few scattered
neurons were located in both the nucleus accumbens shell and core
(Figure 3B).
Within the neocortex two regions were observed that showed pop-
ulations of GLP-1R neurons, the piriform and cingulate cortices
(Figures 2, 3A, 5B, C). The remainder of the cortex was virtually devoid
of GLP-1R neurons with very occasional rare scattered neurons found,
as indicated in Figure 2.
The mesolimbic system exhibited high densities of GLP-1R neurons in
the BNST (Figure 3C), the amygdala (Figure 3D) and the lateral septum
(LS; Figure 3E). Interestingly, only few somata were identiﬁed in the
ventral tegmental area (VTA) (Figure 4E) and NAc (Figure 3B), although
both areas have previously been investigated in relation to the effects
of GLP-1R activation on food intake in rats.
3.2. Co-localisation with catecholamine neurons
Catecholamine neurons were revealed through immunoﬂuorescent
labelling of tyrosine hydroxylase (TH) on brains of GLP-1R-eYFP mice.
In the medulla, TH-immunoreactive neurons were identiﬁed throughout
the AP, NTS and ventrolateral medulla (VLM). Within these areas, a
subset of TH-immunoreactive neurons co-localised with eYFP
expression (Figure 4AeC). Within the AP the majority of TH-
immunoreactive neurons were localised at the dorsal surface, and in
agreement with previously published work demonstrating GLP-1 re-
ceptors on these cells [19], almost all TH neurons co-expressed eYFP.
Within the NTS, TH-immunoreactive neurons were most commonly
located towards the midline, whereas eYFP expressing cells were more
commonly expressed towards the lateral edge, however, there were a
few instances where colocalisation occurred (Figure 4 A, B).
TH-immunoreactive neurons were found scattered throughout the
VLM, and around half were found to co-localise with eYFP positive
neurons (Figure 4C, G). However the number of eYFP positive neurons
observed was much greater when compared with TH-immunoreactive
neurons. Altogether, only a small proportion of GLP-1R neurons in the
VLM were found to be TH-immunoreactive.
The midbrain VTA has a high density of TH-immunoreactive neurons
throughout, but a low level of eYFP-positive somata (Figure 4E, H, I). Of
these eYFP-positive neurons, a small number, predominantly located
on the ventral border, were found to contain TH-immunoreactivity.MOLECULAR METABOLISM 4 (2015) 718e731  2015 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.comWithin the hypothalamus, TH-immunoreactive neurons were found
scattered throughout the dorsomedial hypothalamus (DMH), a small
proportion of these were found to co-stain for eYFP (Figure 4D, F).
However the majority of GLP-1R neurons in the DMH were not TH-
immunoreactive. TH-immunoreactive neurons were also identiﬁed in
the PVN, with the highest densities located in the caudal PVN. Here, no
eYFP neurons were identiﬁed as being TH immunoreactive, however
eYFP neurons were interspersed amongst TH-immunoreactive
neurons.
3.3. Co-localisation with parvalbumin neurons
Parvalbumin (PARV)-immunoreactive neurons were predominately
found in the hippocampus, cortex and thalamus (Figure 5AeC). In the
thalamus, PARV staining was restricted to the reticular nucleus and
superior colliculus. Within these regions, no cells were found to be
immunoreactive for both RFP and PARV. Similarly, in the hippocampus,
cortex and reticular nucleus, populations of both RFP- and PARV-
immunoreactive neurons intermingled, but the two antigens were
not found to co-localise.
3.4. Co-localisation with GFAP
Astrocytes were detected by immunoﬂuorescent labelling of glial
ﬁbrilliary acidic protein (GFAP) in GLP-1R-eYFP brain sections
(Figure 5DeG). Within the dorsal vagal complex (DVC), GFAP-
immunoreactive cells were observed throughout the dorsal motor
nucleus of the vagus (DMNX), the midline of the NTS and along the
border of the AP. No co-localisation between eYFP immunoﬂuores-
cence and GFAP immunoﬂuorescence was observed in the NTS or the
DMNX. GFAP staining was predominately observed along the midline of
the DVC, whereas eYFP-positive cells were generally observed more
laterally. Within the AP, although both GFAP-positive and eYFP-positive
cells were found, no co-localisation was observed (Figure 5D).
Similarly in the hypothalamic PVN, GFAP was observed predominately
around the border of the 3rd ventricle, with scattered processes
observed throughout the PVN. No eYFP-positive cell was observed to
contain GFAP immunoreactivity (Figure 5E). The ARC contained rela-
tively large numbers of GFAP positive cells, but, again, there was no
evidence of co-expression of eYFP-immunoﬂuorescence and GFAP in
individual cells (Figure 5F). A similar observation was also made in the
rostral CA3 region of the hippocampus, that exhibited a number of
GLP-1R cells, but none of these were immunoreactive for GFAP
(Figure 5G).
3.5. Selective targeting of GLP-1R neurons in vivo
Expression of cre-recombinase in cells where the GLP-1R promoter is
active enabled the functional manipulation of GLP-1R neurons in vivo.
We injected EF1a-double ﬂoxed-hChR2(H134R)-EYFP AAV particles
into the PVN to express ChR2-eYFP selectively in PVN GLP-1R neurons
only (Figure 6A). Axons expressing ChR2-eYFP were primarily found in
the caudal NTS (Figure 6B, C) and to a much smaller extent in the VLM
(not shown).
3.6. Electrical responses of GLP-1R neurons to GLP-1 in vitro
In order to verify that tdRFP- or eYFP-immunoreactive neurons did
indeed express GLP-1R and that the receptor is functional, whole-cell
patch-clamp recordings were performed on tdRFP-neurons in three
different brain regions in an in vitro brain slice preparation.
3.6.1. PVN
Seven red-ﬂuorescent PVN neurons were recorded in voltage clamp at
a holding potential of50 mV, and ﬁve cells were recorded in current-pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 723
Figure 3: GLP-1 receptors in the meso-limbic system. Photomicrographs of YFP-immunoreactive cells in (A) cingulate cortex, (B) the nucleus accumbens, lateral septum,
claustrum and cortex, (C) the bed nucleus of the stria terminals, (D) amygdala and ventral posteromedial thalamic nuclei, and (E) the dorsal lateral septum. Abbr: Cl:
claustrum, CTX: cortex, ant comm: anterior commissure, CeA: central amygdala, LS: lateral septum, MeA: medial amygdala, VPM: ventral posteromedial thalamic nuclei. Scale
bars: A, C, E ¼ 200 mm; D ¼ 300 mm; B ¼ 1 mm.
Original articleclamp mode. The mean resting potential in current-clamp mode
was57 2 mV (n¼ 5). Bath-application of 100 nM GLP-1 caused a
depolarisation by 14  1 mV in all ﬁve cells that reversed upon
washout of the drug. In voltage clamp GLP-1 application induced a
reversible inward current of 16  3 pA (n ¼ 7) that was accompanied
by a decrease in membrane resistance from 1.1  0.2 GU to
0.8  0.1 GU (Figure 7AeC, F).724 MOLECULAR METABOLISM 4 (2015) 718e731  2015 The Authors. Published by E3.6.2. BNST
Six BNST neurons were recorded in current clamp. Their resting po-
tential was56 3 mV and bath application of 100 nM GLP-1 elicited
a depolarisation by 8  1 mV that was reversible upon washout of the
drug. An additional ﬁve recordings were performed in voltage clamp at
a holding potential of 50 mV. In these cells GLP-1 caused an inward
current of 10  2 pA (Figure 7D, F).lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
Figure 4: Dual immunoﬂuorescence of GLP-1R-eYFP expressing neurons and tyrosine hydroxylase (TH) expressing neurons throughout the brain. A. Only few TH neurons in the
NTS were found to co-localise with eYFP expressing neurons. Conversely, almost all TH positive neurons in the AP co-expressed GLP-1R. B. Higher magniﬁcation image of boxed
region in A. C. Around half of all TH positive neurons in the RVLM co-expressed GLP-1R, however the majority of GLP-1R neurons were TH-negative. D. A few TH positive neurons
in the DMH were found to have eYFP staining, however the majority did not. E. Only a few TH positive neurons in the VTA expressed GLP-1R. Indeed the VTA contained very few
GLP-1R positive somata. FeI. Scale bars in A, C, D and E ¼ 200 mm. B, F, H and I ¼ 20 mm. G ¼ 50 mm. Arrow heads in B, FeI represent dual labelled neurons. * ¼ YFP positive,
TH negative neurons.3.6.3. Hippocampus
Finally, ﬁve hippocampal pyramidal neurons were recorded in current
clamp and eight cells were recorded in voltage clamp held at50 mV.
The mean resting potential in current-clamp mode was 62  3 mV
(n ¼ 5). Bath-application of 100 nM GLP-1 caused a depolarisation by
8 0.3 mV in four of these cells and a hyperpolarisation of 6 mV in the
remaining cell. Similarly, in voltage clamp six out of eight cells tested
developed a reversible inward current of 20  3 pA under 100 nMMOLECULAR METABOLISM 4 (2015) 718e731  2015 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.comGLP-1 (Figure 7E, F), whereas the remaining two cells exhibited an
outward current of 63 and 36 pA, respectively.
4. DISCUSSION
This study has described the anatomical distribution of tdRFP- or eYFP-
immunoreactive cells throughout the brain, from the spinomedullary
junction through to the prefrontal cortex of the GLP-1R-Cre mouse.pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 725
Figure 5: Dual immunoﬂuorescence of GLP-1R-tdRFP expressing neurons and parvalbumin (PARV) expressing neurons (AeC) and GLP-1R-eYFP expressing cells and GFAP
immunoﬂuorescence (DeG). PARV positive neurons were present in the hippocampus (A), cingulate (B), piriform (C) and thalamic regions (not shown). No tdRFP-positive cell was
found to co-express PARV in any region, although the populations did intermix. Similarly, GFAP was expressed throughout the CNS, and although intermixed with eYFP expression,
no co-expression was identiﬁed. Scale bars in A-F ¼ 200 mm; A’eC’ ¼ 50 mm and G ¼ 500 mm.
Original articleThis mouse uses the Glp1r promoter to drive expression of the enzyme
cre-recombinase, which in turn allows the expression of tdRFP or eYFP
in the ROSA26 locus. These ﬂuorescent markers were used to visually
identify cells, either directly in acute brain slices used for electro-
physiological recordings, or by immunoﬂuorescence in ﬁxed tissue
sections. The extent of cellular labelling was comparable between the
tdRFP and eYFP strains. In both cases, mostly somata and proximal
dendrites were visualised and immunoreactivity did not reveal more
distal dendrites or axons. In contrast to our earlier studies on PPG
neurons [1,13,20], axon projections of GLP-1R neurons could not be
visualised, due to insufﬁcient amounts of RFP or eYFP in these
structures. However, targeting the GLP-1R with AAV constructs as
discussed below led to sufﬁcient expression of the virally-encoded726 MOLECULAR METABOLISM 4 (2015) 718e731  2015 The Authors. Published by Eﬂuorescent marker in the axons of these cells to allow visualisation
of projection targets.
Given that cre-recombinase is expressed under the Glp1r promoter,
tdRFP or eYFP should identify cells that express the GLP-1 receptor.
Clear proof of whether this is indeed the case would be successful
labelling with a GLP-1R antibody. However, the paucity of reliable
GLP-1R antibodies is well established [21,22], and, consequently, a
functional approach was taken in this study. We screened tdRFP-
positive cells in a few brain regions with established (e.g. PVN),
and with questionable (e.g. hippocampus), GLP-1R expression for
electrophysiological responses to GLP-1. The results demonstrated
that tdRFP ﬂuorescence indeed signiﬁed functional responsiveness to
GLP-1, and thus most likely the presence of GLP-1R on these cells.lsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 6: Unilateral microinjection of a cre-dependent AAV expressing ChannelRhodopsin-2 (AAV-ﬂexswitch-ChR2-eYFP) in the hypothalamic PVN. A. ChR2 expression (green) is
conﬁned to the boundaries of the PVN and expressed only in cells which co-express tdRFP (red). (A’) Higher magniﬁcation image of ChR2 expressing tdRFP positive neurons in the
PVN. This study conﬁrms the presence of active cre-recombinase in these cells and provides proof-of-principle evidence that these mice can be used to virally target GLP-1R
expressing cells in discrete nuclei. B, C. ChR2-eYFP expressing axons of virally-targeted PVN neurons are distributed primarily in the caudal NTS up to the rostral end of the
AP. Scale bar A ¼ 100 mm. A’ ¼ 10 mm. B, C ¼ 200 mm. 3V ¼ 3rd ventricle.Inevitably numbers of cells tested in this manner are low, and we
cannot exclude with certainty that some subpopulations of RFP-
immunoreactive cells described in this study might reﬂect either
ectopic expression or lineage tracing [16]. However, within these
potential constraints, the GLP-1R-Cre/ROSA26-tdRFP/eYFP mouse is
an invaluable tool for examining GLP-1 function within the CNS.
Firstly, this mouse obviates the need for notoriously unreliable anti-
bodies for the detection of GLP-1R and therefore offers a greater level
of reliability as antibodies raised against eYFP and tdRFP are
generally less susceptible to non-speciﬁc binding (and their speci-
ﬁcity can be easily tested in brain tissue from wildtype mice). Sec-
ondly, it allows the identiﬁcation of GLP-1R expressing cells in live
slice preparations and thus permits functional characterisation of
deﬁned GLP-1R expressing cells at cellular level in vitro. Finally, it
enables the use of viral gene transfer to manipulate speciﬁc sets of
GLP-1R expressing cells in vivo.
4.1. Distribution of GLP-1R throughout the murine brain
GLP-1R expressing cells were observed throughout the rostrocaudal
extent of the mouse brain, and generally correlated with the projection
targets of brainstem PPG neurons [1,13,23e25] and the expression of
GLP-1R described in rat [14], although some differences were
observed. Interestingly, the expression pattern is also very similar to
that of a non-human primate (Table 1; [15]), which suggests that the
GLP-1 system is largely conserved throughout the brain between
mammalian species. This might not be surprising, given that the
distribution of GLP-1 producing PPG neurons is also quite conserved
between species [1,23,26,27]. The largest numbers of GLP-1R cells
were observed in regions associated with autonomic and behavioural
control of energy balance, such as the PVN, ARC, DMH and central
amygdala. Selective targeting of GLP-1R cells in future studies should
shed light on current controversies such as whether GLP-1 action in
the ARC affects glucose homeostasis or not [28e30]. Many GLP-1R
expressing neurons were also observed in the dorsal lateral septum
(DLS) and in the BNST. The DLS has recently been linked to effects ofMOLECULAR METABOLISM 4 (2015) 718e731  2015 The Authors. Published by Elsevier GmbH. This is an o
www.molecularmetabolism.comGLP-1 on cocaine-induced behaviour [31] and the BNST is a major
projection target for PPG neurons in both rat and mouse [1,32]. The AP
and SFO, which form part of the brains’ circumventricular organs, also
contained large numbers of GLP-1R expressing cells. Moderate
numbers of GLP-1R expressing cells were observed in the ventrolateral
medulla, which like the PVN harbours presympathetic neurons, and
thus both regions might contribute to the effects of GLP-1 on cardio-
vascular control as well as thermogenesis [8,9,33].
Of particular interest were brain areas such as the VTA and NAc, which
have recently received attention for their ability to reduce food intake
and reward behaviour following GLP-1R activation [10,34,35]. In these
regions, there was little GLP-1R expression, in contrast to observations
in rat [14], but in agreement with recent in situ hybridisation studies in
mouse [31]. Indeed, tracing studies in rats have observed that around
30% of NTS PPG neurons project to the VTA and around 40% project to
the NAc [25] suggesting that they are sites of GLP-1 release from
brainstem PPG neurons. In vitro electrophysiological studies in rats
have reported increased glutamatergic signalling onto dopaminergic
neurons by GLP-1 acting via presynaptic receptors [11,12]. It is
therefore possible to speculate that GLP-1Rs in these regions are
present on terminals arising from other sites and the somata of these
neurons would most likely be located in distal nuclei, thus providing an
explanation for the absence of GLP-1R positive cell bodies in the VTA
and NAc. Conversely, this discrepancy could be the result of species
variation, since most in vivo behavioural studies involving the actions of
GLP-1 in these brain regions were performed in rats. This notion may
be supported by the fact that very few PPG axons can be found in the
NAc of mice.
Previous studies have reported the putative existence of GLP-1R on
glial cells throughout the CNS [36,37]. Here, using double immuno-
ﬂuorescence for eYFP and the astroglial marker, GFAP, we found no
co-localisation throughout the brain. This is in agreement with a recent
study that located GLP-1R on microglia, but not astroglia, in rat spinal
cord [38]. It should be noted, however, that immunoﬂuorescent
identiﬁcation of GFAP predominately labelled astrocytic processes,pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 727
Figure 7: GLP-1 elicits electrical responses in GLP-1R-Cre positive cells in various brain regions. A, B. Voltage-clamp recording from an RFP-positive PVN neuron. Bath application
of 100 nM GLP-1 elicited a small inward current at a holding potential of 50 mV accompanied by an increase in whole-cell conductance. These effects reversed upon washout of
GLP-1 from the bath solution. C, D. Similarly, in a BNST neuron bath application of 100 nM GLP-1 elicits an inward current accompanied by an increase in conductance. E. Voltage
clamp recordings in RFP-positive hippocampal neurons revealed that GLP-1 either elicits an inward current (left panel) as in PVN and BNST, or an outward current. F. Mean data
from current clamp recordings (left panel) demonstrating that GLP-1 causes a 10e15 mV depolarisation in most neurons tested, and a hyperpolarisation in individual hippocampal
cells. Mean data from voltage clamp recordings in the right panel demonstrate the inward current of 10e20 pA amplitude elicited by 100 nM GLP-1 underlying the depolarisation in
current clamp. n-numbers are given below the bars. **: p < 0.01.
Original article
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whereas eYFP predominately labelled somata. It is therefore possible
that a more speciﬁc marker for astrocytic somata may reveal the
existence of GLP-1R on glial cells. However, transcriptome analysis of
astrocytes failed to demonstrate signiﬁcant expression of GLP-1R [39]
(see also: http://www.networkglia.eu/en/transcriptome).
4.2. Projections from GLP-1R expressing PVN neurons
Unilateral injections of AAV into the PVN demonstrated that these
neurons express cre-recombinase in the adult animal. Cre-
recombinase expression is driven by the GLP-1R promoter, indi-
cating that the red ﬂuorescent PVN neurons do express GLP-1R. Indeed
electrophysiological recordings from a small number of these neurons
conﬁrmed that GLP-1 elicits an inward current and depolarisation in
these cells. Activation of the AAV Flex-switch in the injected animals
led to the expression of ChR2-eYFP embedded in the membrane of the
transduced cells, which enabled analysis of their speciﬁc projection
patterns. It was noteworthy that a particularly high density of varicose
axons from the PVN GLP-1R neurons was observed in the NTS and
DMNX, whereas other known projection targets of PVN neurons, such
as the VLM received substantially fewer axon terminals. This ﬁnding is
in line with studies that found a similar distribution of PVN projections
in rat [40e42]. It remains to be established if part of this projection
constitutes a feedback loop to modulate the activity of PPG neurons in
the NTS. Given that in rat most neurons in the medial NTS, which
receive input from unidentiﬁed PVN neurons have been shown to be
responsive to gastric distension [43], like the PPG neurons, this seems
a distinct possibility.
4.3. GLP-1R in hippocampus
Various studies have reported effects of GLP-1 in hippocampus, both
at the cellular and systemic levels [6,44]. A recent study even re-
ported a reduction in food intake upon injection of Ex-4 into the
hippocampus [45]. However, in the absence of any clear innervation
with GLP-1 containing axons from PPG neurons in rodents or pri-
mates [1,23,26], it is difﬁcult to imagine the source of GLP-1 in
hippocampus. Nevertheless, whilst non-human primates do not
seem to express GLP-1R in hippocampus [15], both in situ hybrid-
isation and the current study identify GLP-1R in parts of the hippo-
campus of rat and mouse, respectively [14]. The study by
Merchenthaler and colleagues reported GLP-1R mRNA expressing
cells in the ventral hippocampus of rat, particularly in the CA3 region
[14]. The current study conﬁrmed this in mouse, but also identiﬁed a
small, succinct group of pyramidal cells in the rostral CA3. In
contrast, GLP-1 binding studies failed to identify the hippocampus as
a target [46]; however, since cell numbers in this region were low, it
could be below the detection limit. Additionally, here we show
electrical responses of individual identiﬁed red ﬂuorescent hippo-
campal neurons to GLP-1. The recordings indicated two types of
electrical responses, either the activation of an inward current,
presumably a non-selective cation channel, or the activation of a Kþ
current. The former is an excitatory and the latter an inhibitory
response. The combination of the ﬂuorescence identiﬁcation and the
electrical responsiveness of these cells makes it highly likely that
these hippocampal neurons indeed express GLP-1 receptors. This
raises the question of whether these cells would be exposed to GLP-1
in vivo, and, if so, where would this GLP-1 originate? It has been
proposed that GLP-1 could reach the hippocampus from the cere-
brospinal ﬂuid (CSF), and indeed detectable levels of GLP-1 were
found in CSF samples [45]. However, whether CSF GLP-1 originates
from gut-derived GLP-1 or is released into the CSF by PPG neurons is
currently unclear.MOLECULAR METABOLISM 4 (2015) 718e731  2015 The Authors. Published by Elsevier GmbH. This is an o
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GLP-1Rs are expressed in regions protected by the blood brain barrier
(BBB) as well as those outside. This provides two possible mechanisms
through which GLP-1 may exert actions within the brain. It is generally
believed that the rapid degradation of GLP-1 in the blood by circulating
DPP-IV prevents gut secreted GLP-1 from crossing the BBB [47].
Receptors expressed on cells within circumventricular organs provide
a mechanism by which circulating GLP-1 may exert actions within the
brain. Indeed, it has been shown that GLP-1 responsive catechol-
aminergic neurons in the AP project to areas associated with auto-
nomic control, including the parabrachial nucleus and RVLM [19].
However, the existence of GLP-1R in regions protected by the BBB
suggests that brain-derived GLP-1 is involved in regulating at least
some of the responses attributed to GLP-1 action in the brain. This is
further supported by the existence of receptors in regions, which
receive dense innervation from brainstem PPG neurons [1,13,23e25].
On the other hand, two of the circumventricular organs, the AP and the
SFO, express a high density of GLP-1 receptor cells, but show a rather
limited amount of innervation from PPG axons [1,13]. This might point
to a role for peripheral GLP-1 in these regions, or to a role for CSF GLP-
1. Further work will be needed to fully elucidate the relative contri-
bution of brain-derived vs peripherally-derived GLP-1 on the brain GLP-
1 system.
Previous in vitro electrophysiological work has focussed on the VTA
and NAc. It has been suggested that GLP-1Rs exert their effect through
a pre-synaptic enhancement of glutamate release in the VTA and NAc
[11,12]. In contrast, in the regions investigated in our study, we
consistently showed whole-cell currents elicited by GLP-1 in RFP-
positive neurons, indicative of post-synaptic GLP-1 receptors, activa-
tion of which opens a non-selective cation channel in most cells or a
Kþ channel in some hippocampal neurons. This discrepancy could
indicate why few GLP-1R containing cell bodies are observed in the
VTA and NAc in our study and that of Harasta et al. [31]. If they are
expressed on axons terminals, their cells bodies may be located in
distal nuclei. This would explain why microinjection of GLP-1 or Ex-4
into the VTA and the NAc [10,34,35] elicits functional effects, but
few GLP-1R-expressing cell bodies are found in these regions. Alter-
natively, a species-difference between rat and mouse might exist,
leaving mouse insensitive to GLP-1 in the VTA and NAc.
4.5. Conclusions
In this study, we have demonstrated that this mouse model provides
not only the means to describe the distribution of GLP-1R expressing
cells throughout the brain facilitating identiﬁcation and functional
characterisation in vitro, but also that it is amenable to genetic tar-
geting of GLP-1R cells with cre-dependent viral gene expression.
These properties will allow future studies of functional interference
with speciﬁc subsets of GLP-1R expressing cells in vivo, as well as
circuit mapping, and development of bespoke mouse strains con-
taining knock outs of desired proteins in GLP-1R expressing cells.
The difﬁculty of identifying neurons expressing the GLP-1R is made all
the more complex by the lack of reliable antibodies. Here we have
circumnavigated this problem by using a transgenic mouse, which
expresses Cre recombinase under the control of the Glp1r promoter.
Although this negates the need for antibodies to detect the expression
of the GLP-1R, it is noteworthy that the expression of ﬂoxed ﬂuorescent
proteins requires only Glp1r promoter activity at some point during
development [48], and does not necessarily reﬂect current GLP-1R
expression. Validation has been previously carried out on this model
in peripheral cells [16], but full validation of the central expressing
neurons will require future work. The current study has achieved muchpen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 729
Original articletowards addressing this question by employing both electrophysio-
logical recordings and viral gene transfer to address the question of
whether GLP-1R and cre-recombinase are both expressed in fully
developed adult animals at the time of experimentation; in all instances
tested here this was the case.
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